首页|双歧杆菌三联活菌联合标准四联疗法治疗Hp感染慢性胃炎患者的效果

双歧杆菌三联活菌联合标准四联疗法治疗Hp感染慢性胃炎患者的效果

扫码查看
目的:观察双歧杆菌三联活菌联合标准四联疗法治疗幽门螺杆菌(Hp)感染慢性胃炎患者的效果.方法:选取 2021 年6 月至 2023 年 6 月该院收治的 85 例Hp感染慢性胃炎患者进行前瞻性研究,按照随机数字表法将其分为研究组 43 例与对照组 42 例.对照组采用标准四联疗法治疗,研究组在对照组基础上联合双歧杆菌三联活菌散治疗,比较两组临床疗效、治疗前后炎性指标[C反应蛋白(CRP)、降钙素原(PCT)、E-钙黏蛋白、环氧化酶-2(COX-2)]水平、胃肠功能指标[胃蛋白酶原Ⅰ(PGⅠ)、胃泌素-17(G-17)、糖类抗原 724(CA724)]水平、肠道菌群水平和不良反应发生率.结果:研究组治疗总有效率为 95.35%(41/43),高于对照组的 78.57%(33/42),差异有统计学意义(P<0.05);两组CRP、PCT、COX-2、E-钙黏蛋白水平均低于治疗前,且研究组低于对照组,差异有统计学意义(P<0.05);两组PGⅠ和G-17水平均高于治疗前,且研究组高于对照组,两组CA724水平均低于治疗前,且研究组低于对照组,差异有统计学意义(P<0.05);两组双歧杆菌、丁酸梭菌水平均高于治疗前,且研究组高于对照组,两组肠杆菌水平均低于治疗前,且研究组低于对照组,差异有统计学意义(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05).结论:双歧杆菌三联活菌联合标准四联疗法治疗Hp感染慢性胃炎患者可提高治疗总有效率,改善胃肠功能指标和肠道菌群水平,降低炎性指标水平,其效果优于单纯标准四联疗法治疗.
Effects of Bifidobacterium triple viable bacteria combined with standard quadruple therapy in treatment of patients with Hp infected chronic gastritis
Objective:To observe effects of Bifidobacterium triple viable bacteria combined with standard quadruple therapy in treatment of patients with Helicobacter pylori(Hp)infected chronic gastritis.Methods:A prospective study was conducted on 85 patients with Hp infected chronic gastritis admitted to the hospital from June 2021 to June 2023.According to the random number table method,they were divided into study group(43 cases)and control group(42 cases).The control group was treated with standard quadruple therapy,while the study group was treated with Bifidobacterium triple viable bacteria powder on the basis of that of the control group.The clinical efficacy,the inflammatory factor[C-reactive protein(CRP),procalcitonin(PCT),calcium adhesion protein E,cyclooxygenase-2(COX-2)]levels,the gastrointestinal function indexes[pepsinogen I(PGⅠ),gastrin-17(G-17),carbohydrate antigen 724(CA724)]levels,the intestinal flora levels,and the incidence of adverse reactions were compared between the two groups before and after the treatment.Results:The total effective rate of treatment in the study group was 95.35%(41/43),which was higher than 78.57%(33/42)in the control group,and the difference was statistically significant(P<0.05).The levels of CRP,PCT,COX-2 and cadherin E in the two groups were lower than those before the treatment,those in the study group were lower than those in the control group,and the differences were statistically significant(P<0.05).The levels of PGⅠ and G-17 in the two groups were higher than those before the treatment,and those in the study group were higher than those in the control group;the levels of CA724 in the two groups were lower than those before the treatment,and that in the study group was lower than that in the control group;and the differences were statistically significant(P<0.05).The levels of Bifidobacterium and Clostridium butyricum in the two groups were higher than those before the treatment,and those in the study group were higher than those in the control group;the levels of Enterobacteriaceae in the two groups were lower than those before the treatment,and that in the study group was lower than that in the control group;and the differences were statistically significant(P<0.05).However,there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusions:Bifidobacterium triple viable bacteria combined with standard quadruple therapy in the treatment of the patients with Hp infected chronic gastritis can improve the total effective rate of treatment,improve the gastrointestinal function index and intestinal flora levels,and reduce the levels of inflammatory factor.Moreover,it is superior to single standard quadruple therapy.

Bifidobacterium triple viable bacteriaStandard quadruple therapyHp infected chronic gastritisGastrointestinal functionIntestinal flora

安宏杰、尉佳林、杨小慧

展开 >

中国人民解放军陆军第九四七医院,消化呼吸内科,新疆 喀什 844200

中国人民解放军陆军第九四七医院,特诊科,新疆 喀什 844200

双歧杆菌三联活菌 标准四联疗法 Hp感染慢性胃炎 胃肠功能 肠道菌群

2024

中国民康医学
中国社会工作协会

中国民康医学

影响因子:0.649
ISSN:1672-0369
年,卷(期):2024.36(3)
  • 13